GO
Loading...

Acquisitions

More

  • Softbank in Talks With Sprint     Thursday, 11 Oct 2012 | 10:55 AM ET

    James Moorman, S&P Capital IQ analyst, discusses how the wireless landscape could change if Softbank acquires 75 percent of Sprint.

  • Sprint Shares Soar on Softbank Talks     Thursday, 11 Oct 2012 | 10:07 AM ET

    CNBC's David Faber reports the latest details on news that Japanese mobile carrier Softbank is in talks to acquire 75 percent of Sprint Nextel, in a deal that could top $12.8 billion.

  • CNBC's David Faber reports Japan's Softbank is in talks to acquire a majority stake in Sprint Nextel.

  • CNBC's David Faber has the latest details on a report Softbank is negotiating to buy 75 percent of Sprint Nextel.

  • Jana Turns up Heat on Agrium     Monday, 1 Oct 2012 | 2:51 PM ET

    Hedge fund heavy weights have been swapping investment ideas at the annual Value Investing Congress. Barry Rosenstein, Jana Partners founder, and CNBC's David Faber, discuss owning Agrium.

  • After Nexen, CNOOC May Target BP's Stake in TNK Wednesday, 26 Sep 2012 | 7:48 PM ET

    Energy-hungry China may not be done yet on the acquisition trail.

  • M&T Bank to Buy Hudson City Bancorp     Monday, 27 Aug 2012 | 8:22 AM ET

    CNBC's Kayla Tausche has the details on the $3.7 billion deal.

  • Baer Likely to Buy BofA Unit: Report     Friday, 10 Aug 2012 | 10:40 AM ET

    CNBC's Kate Kelly has the details on a possible sale of Bank of America's non-U.S. wealth unit to Julius Baer for between $1 billion to $1.5 billion.

  • CNOOC’s Failed Unocal Bid Paved Way for Nexen Deal Tuesday, 24 Jul 2012 | 3:39 AM ET

    The memory of  its failed 2005 bid for Unocal still fresh, China's state-controlled CNOOC Ltd. has put lessons learned into practice and "networked strongly" with regulators in Canada and the U.S., smoothing the way for its $15.1 billion all-cash deal to  buy Canadian oil producer Nexen Inc.

  • Glaxo to Buy Human Genome Sciences     Monday, 16 Jul 2012 | 10:26 AM ET

    CNBC's David Faber reports Glaxo will buy Human Genome for $14.24 per share, and TPG acquires generic drugmaker Par Pharma.

  • CNBC's David Faber reports the latest details on GlaxoSmithKline's takeover bid for Human Genome Science.

  • BlackBerry: Rotten or Ripe?     Tuesday, 10 Jul 2012 | 11:00 AM ET

    CNBC's Jon Fortt reports the latest details from RIM's annual shareholders meeting and Colin Gillis, BGC Partners analyst, discusses whether there are investment opportunities in the stock despite its downward spiral.

  • Roadmap to Monday's Market     Monday, 9 Jul 2012 | 9:00 AM ET

    The "Squawk on the Street" news crew reports on what's going to drive the "buzz" and trading today, including the kick off to earnings season, and Wellpoint's acquisition of rival, Amerigroup.

  • Microsoft Takes $6.2 Billion Charge     Tuesday, 3 Jul 2012 | 11:40 AM ET

    Microsoft admits its acquisition of AQuantive is pretty much worthless now, with CNBC's Herb Greenberg.

  • Are Global Markets Losing M&A Appetite?     Thursday, 28 Jun 2012 | 7:32 AM ET

    A look at how uncertainty in global markets is impacting deal-making on Wall Street, with Ken Moelis, Moelis & Company founder & CEO.

  • Cinemagram: 'Next' Instagram?     Wednesday, 27 Jun 2012 | 11:41 AM ET

    This company has attracted more than two million users since it launched in March, making it one of the fastest growing photo-sharing platforms. Temo Chalasani, Cinemagram CEO & co-founder, discusses new trends in mobile apps and how he plans to outpace competitors.

  • Breaking News: Cisco's Hooper Leaving Company     Tuesday, 26 Jun 2012 | 12:45 PM ET

    Cisco's strategy chief, Ned Hooper is leaving the company, reports CNBC's Jon Fortt. The FMHR traders, weigh in.

  • Gigantic movie house, The Weinstein Company, has just secured $225 million in financing from UBS and Union Bank. CEO Harvey Weinstein discusses how his company will use the money to grow their business, the company's overseas success, the "Intouchables," and politics.

  • CNBC's David Faber breaks down the details on Walgreen's $6.7 billion acquisition of Alliance Boots, making it the largest buyer of pharmaceuticals in the world.

  • Roadmap for Tuesday's Markets     Tuesday, 19 Jun 2012 | 9:00 AM ET

    The "Squawk on the Street" news crew reports on where the rally is headed next; Microsoft's new tablet; JC Penney's executive shuffle; and Walgreen's deal to buy Alliance Boots for $6.7 billion in cash.